Evidence map›Paper›PMID 33031440›Full record

ArticlePloS one2020

The impact of user fees on uptake of HIV services and adherence to HIV treatment: Findings from a large HIV program in Nigeria.

Aima A Ahonkhai, Susan Regan, Ifeoma Idigbe, Olayemi Adeniyi, Muktar H Aliyu, Prosper Okonkwo, Juliet Adeola, Elena Losina, Zaidat Musa, Oliver Ezechi and 1 more

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aima A AhonkhaiDivision of Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.ORCID 0000-0003-0666-4767
Susan ReganDivision of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Ifeoma IdigbeNigerian Institute for Medical Research, Lagos, Nigeria.
Olayemi AdeniyiNigerian Institute for Medical Research, Lagos, Nigeria.
Muktar H AliyuVanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Prosper OkonkwoAPIN Public Health Initiatives (APIN), Abuja, Nigeria.
Juliet AdeolaAPIN Public Health Initiatives (APIN), Abuja, Nigeria.
Elena LosinaMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Zaidat MusaNigerian Institute for Medical Research, Lagos, Nigeria.
Oliver EzechiNigerian Institute for Medical Research, Lagos, Nigeria.
Kenneth A FreedbergMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America.

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
"Implementation of Programs for Prevention, Care and Treatment of HIV/AIDS in theU2GPS001058 · PS · AIDS PREVENTION INITIATIVE IN NIGERIA · PI OKONKWO, PROSPER IFEANACHO · 2008 to 2013
$83.4M
Optimizing HIV Care in Less Developed CountriesR01AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Emily Parker Hyle · 2004 to 2026
$21.5M
Optimizing HIV Care in Less Developed CountriesR37AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI FREEDBERG, KENNETH ALAN · 2018 to 2024
$6.6M
What happens after diagnosis: Characterizing long-term HIV care trajectories and mortality in South AfricaR01MH108427 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI BASSETT, INGRID VALERIE · 2016 to 2019
$1.7M
Decreasing Interruptions and Losses from HIV Care in NigeriaK23AI106406 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI AHONKHAI, AIMALOHI · 2013 to 2017
$914k
NCHHSTP CDC HHS U2G PS001058NIAID NIH HHS K23 AI106406NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI058736NIMH NIH HHS R01 MH108427
6 · The paper itself

Abstract

backgroundGlobal HIV funding cutbacks have been accompanied by the adoption of user fees to address funding gaps in treatment programs. Our objective was to assess the impact of user fees on HIV care utilization and medication adherence in Nigeria.

methodsWe conducted a retrospective analysis of patients enrolled in care before (October 2012-September 2013) and after (October 2014-September 2015) the introduction of user fees in a Nigerian clinic. We assessed pre- vs. post-user fee patient characteristics and enrollment trends, and determined risk of care interruption, loss to follow-up, and optimal medication adherence.

resultsAfter fees were instituted, there was a 66% decline in patient enrollment and 75% decline in number of ART doses dispensed. There was no difference in the proportion of female clients (64% vs 63%, p = 0.46), average age (36 vs. 37 years, p = 0.15), or median baseline CD4 (220/ul vs. 222/uL, p = 0.24) in pre- and post-fee cohorts. There was an increase in clients employed and/or had tertiary education (24% vs. 32%, p<0.001). Compared to pre-fee patients, the post-fee period had a 48% decreased risk of care interruption (aRR = 0.52, 95%CI:0.39-0.69), 22% decreased LTFU risk (aRR = 0.64, 95%CI:0.96), and 27% decreased odds of optimal medication adherence (aOR = 0.7, 3 95%CI 0.59-0.89).

conclusionsPatients enrolled in care after introduction of user fees in Nigeria were more likely to be educated or employed, and effectively retained in care after starting ART. However, fees were accompanied by a drastic reduction in new patient enrollment, suggesting that many patients may have been marginalized from HIV care.

Indexed as

Medication AdherenceAdultAmbulatory Care FacilitiesAnti-HIV AgentsCohort StudiesFees and ChargesFemaleHealth ExpendituresHIV InfectionsHumansLost to Follow-UpMaleNigeriaPatient DropoutsRetrospective StudiesAnti-HIV Agents

Identifiers

PMID33031440
PMCPMC7544141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.